Seagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance

 -Record Net Product Sales of $544 Million in 2Q23, an Increase of 26% Over 2Q22, Contributing to Total Revenues of $604 Million in 2Q23-

-Strong PADCEV^® Growth Driven By Combination First-Line Advanced Urothelial Cancer Launch; Record ADCETRIS^® Performance with Overall Survival Benefit Demonstrated in the ECHELON-1 Trial Added to Label-

-Three Registrational Trial Readouts for PADCEV, TUKYSA^® and TIVDAK^® Anticipated in 2H23-

-Initiated Phase 3 Trial for Disitamab Vedotin and Expect to Initiate Phase 3 Trial of SGN-B6A by Year End-

-Proposed Acquisition by Pfizer Progressing Towards Close in Late 2023 or Early 2024-

https://www.biospace.com/article/releases/seagen-second-quarter-2023-financial-results-demonstrate-exceptional-commercial-performance-driving-record-product-sales-with-strong-growth-and-momentum/